Back to Journals » Patient Preference and Adherence » Volume 10

Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting

Authors Gohil R, Crosby-Nwaobi R, Forbes A, Burton B, Hykin P, Sivaprasad S

Received 1 February 2016

Accepted for publication 29 February 2016

Published 26 May 2016 Volume 2016:10 Pages 949—955

DOI https://doi.org/10.2147/PPA.S105536

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Doris Leung

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen

Rishma Gohil,1,2 Roxanne Crosby-Nwaobi,1,2 Angus Forbes,2 Ben J Burton,3 Philip Hykin,1 Sobha Sivaprasad1,4

1National Institute for Health Research Moorfields Biomedical Research Centre, London, 2Diabetes Nursing, King’s College London, London, 3Ophthalmology Department, James Paget University Hospital, Great Yarmouth, 4Laser and Retinal Research Unit, King’s College Hospital, London, UK


Context: Treatment satisfaction with a loading phase of monthly injections for 3 months followed by a pro-re-nata regimen of ranibizumab in neovascular age-related macular degeneration (nAMD) remains unclear.
Aims: The aim was to evaluate the treatment satisfaction of persons with nAMD treated with ranibizumab in a real-life setting.
Settings and design: A cross-sectional study was conducted across three eye clinics within the National Health Service in the UK, where treatment is provided free at point of contact.
Materials and methods: A total of 250 patients were selected randomly for the study. Treatment satisfaction was assessed using the Macular Treatment Satisfaction Questionnaire. Data were collected on satisfaction of the service provided (Client Service Questionnaire-8) and the patients’ demographic and quality of life and treatment history. Factors governing treatment questionnaire were determined.
Results: The most important factors that determined the satisfaction were the service provided at the clinic (Client Service Questionnaire-8), health-related quality of life (EQ-5D-3L), and duration of AMD. Visual acuity changes were rated as less important than one would have expected.
Conclusion: The study result suggested that treatment satisfaction for nAMD was governed by the perception of being reviewed and injected regularly over a long period of time than the actual change in visual acuity from the treatment.

Keyword: macular treatment satisfaction questionnaire, patient related outcome measure, treatment history, quality of life

A Letter to the Editor has been received and published for this article. 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Health-related quality of life, visual function and treatment satisfaction following intravitreal dexamethasone implant for diabetic macular edema

Ramu J, Chatziralli I, Yang Y, Menon G, Bailey C, Eckstein M, Hykin P, Sivaprasad S

Patient Preference and Adherence 2017, 11:579-586

Published Date: 17 March 2017

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion

Sivaprasad S, Oyetunde S

Clinical Ophthalmology 2016, 10:939-946

Published Date: 24 May 2016

An exploratory study evaluating the effects of macular carotenoid supplementation in various retinal diseases

Crosby-Nwaobi R, Hykin P, Peto T, Sivaprasad S

Clinical Ophthalmology 2016, 10:835-844

Published Date: 11 May 2016

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK

Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S

Clinical Ophthalmology 2016, 10:87-96

Published Date: 13 January 2016

Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK

Sobha Sivaprasad, Nachiketa Acharya, Phil Hykin

Clinical Ophthalmology 2008, 2:347-354

Published Date: 6 June 2008